Last reviewed · How we verify
Severe growth hormone deficiency in adulthood
Approved treatments
- Omnitrope · Sandoz
- Omnitrope · Serono
Somatropin binds dimeric GH receptors on target cells, inducing intracellular signaling and GH-dependent protein synthesis including IGF-1. - somatropine · Sanofi
Clinical guidelines
- FDA label — 1L
Replacement of endogenous GH in adults with growth hormone deficiency (GHD) - FDA label — 1L
Somatropin (Omnitrope) is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Severe growth hormone deficiency in adulthood patent landscape — cliff calendar, originator estates, attackable patents
- Severe growth hormone deficiency in adulthood treatment landscape brief
- Severe growth hormone deficiency in adulthood treatment updates RSS
Frequently asked questions about Severe growth hormone deficiency in adulthood
What drugs treat Severe growth hormone deficiency in adulthood?
Tracked treatments include Omnitrope, somatropine.
What is the treatment for Severe growth hormone deficiency in adulthood?
Standard treatment for Severe growth hormone deficiency in adulthood includes Omnitrope, somatropine. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Severe growth hormone deficiency in adulthood?
FDA label publishes guidelines for Severe growth hormone deficiency in adulthood. 2 guideline references tracked.
Related
- Treatment landscape: Severe growth hormone deficiency in adulthood patent cliff · Severe growth hormone deficiency in adulthood CI report
- Treatment: Omnitrope · Sandoz
- Treatment: Omnitrope · Serono
- Treatment: somatropine · Sanofi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing